Indication name: Chordoma
"Chordoma – Market outlook,
Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
(Markets covered: US, Germany, France, Spain, United Kingdom, Italy, Japan
& China)
A chordoma is a rare type of
cancerous tumor that can occur anywhere along the spine, from the base of the
skull to the tailbone. Chordomas grow slowly, gradually extending into the bone
and soft tissue around them. Changes in the TBXT gene have been associated with
chordoma. The TBXT gene provides instructions for making a protein called
brachyury.
According to Thelansis, worldwide
one in one million people are diagnosed with chordoma per year.
Competitive landscape of Chordoma
includes country specific approved as well as pipeline therapies. Any asset/
product specific designation or review and Accelerated Approval are being
tracked and supplemented with analyst commentary.
KOLs insights of Chordoma across
8 MM market from center of Excellence/ Public/ Private hospitals participated
in the study. Insights around current treatment landscape, epidemiology,
clinical characteristics, future treatment paradigm and Unmet needs.
Chordoma Market Forecast: Patient
Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs
with sourcing, Market Event and Product Event, Country specific Forecast Model,
Market uptake and patient share uptake, Attribute Analysis, Analog Analysis,
Disease burden and pricing scenario, Summary and Insights.
S. No Asset Company Stage
1 TAEK-VAC-HerBy Bavarian Nordic Phase 2
2 GI-6301 NantCell, Inc. Phase
2
3 FAZ053 Novartis Pharmaceuticals Phase 1
4 Nivolumab Bristol-Myers Squibb Phase 2
5 Pemetrexed Eli Lilly and Company Phase 1
6 Afatinib Boehringer Ingelheim Phase 2
7 BCA101 Bicara Therapeutics Phase 1
No comments:
Post a Comment